Tuesday, 25 April 2017
Latest news
Main » Johnson & Johnson says pricing competition squeezing sales

Johnson & Johnson says pricing competition squeezing sales

19 April 2017
Johnson & Johnson says pricing competition squeezing sales

Landmark Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 0.5% in the fourth quarter.

Modest growth across the board led to the company's largely flat operational growth of 1% year over year, excluding acquisition and divestitures. Keystone Financial Planning Inc. raised its stake in shares of Johnson & Johnson by 0.3% in the third quarter.

J&J expects adjusted earnings per share in the range of $7.00 - $7.15 for 2017 compared with $6.93 to $7.08 expected previously. Finally, Valicenti Advisory Services Inc. increased its stake in shares of Johnson & Johnson by 0.7% in the third quarter. Stock traders acquired 3,039 put options on the company.

As the earnings date approaches, we can see that insider ownership is now 0.02% shares, and institutional ownership is at 67.40% for Johnson & Johnson (NYSE:JNJ) stock. Following the completion of the transaction, the vice president now directly owns 127,650 shares in the company, valued at approximately $14,972,068.50. Intact Investment Management Inc.'s holdings in Johnson & Johnson were worth $18,070,000 at the end of the most recent quarter.

Half a million Iraqis displaced in Mosul operation
Earlier this year, Al Qaeda's leader repeated criticism of the Islamic State's violent attacks, such as beheadings of civilians. According to the top USA commander in Iraq, the battle for Western Mosul is the most brutal urban combat since World War II.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 124.99 on Friday. The stock now shows its YTD (Year to Date) performance of 9.84 percent while its Weekly performance value is 0.64%.

The stock increased 0.58% or $0.73 during the last trading session, hitting $125.77. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of 0.19%.

Johnson & Johnson (NYSE:JNJ)'s earnings is on the doorstep as the firm is set to report on 4/18/2017 8:30:00 AM. The current consensus recommendation provided by covering analysts is 2.50.

Sales came in at $17.77 billion, missing the Zacks Consensus Estimate of $18.0 billion by 1.3%. The Return on Investment (ROI) is at 17% while it's Return on Equity (ROE) value stands at 22.9%. The company's quarterly revenue was up 1.7% on a year-over-year basis. The company's quarterly revenue was up 1.6% on a year-over-year basis.

Kelly says critical lawmakers should changes laws or shut up
Southern Command, overseeing security operations for Central America, South America and the Caribbean. Marijuana is VERY much a factor in the War on Drugs . "Let me be clear about marijuana".

The Band-Aid maker got off to a rocky start this year, forecasting in January sales and profit for 2017 below Street estimates, and said it expected a slower growth rate for pharmaceuticals in the year.

Argus Research Upgrades Johnson & Johnson (JNJ) to Buy with a price target of $145. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $129.00. Jefferies Maintains the company's stock to Hold on 8/04/16 by setting a price target of $119. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the company's stock. Finally, Royal Bank of Canada reduced their target price on shares of Johnson & Johnson from $133.00 to $128.00 and set an "outperform" rating on the stock in a research note on Wednesday, January 25th.

J&J in February agreed to sell its Codman neurosurgery business for more than $1 billion. The shares were sold at an average price of $117.29, for a total transaction of $2,580,380.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the past few months, insider ownership has seen a move of -20.22% while institutional ownership has changed -0.11%.

AMD RX 500 Series Launched; Pricing Details Now Available
We will bring the complete specifications of the AMD Radeon RX 500 Series graphics card once information becomes available. The 2GB RX 560 launches in early May for £99, while the 2GB RX 550 launches on April 20 for a wallet-friendly £80.